- Home
- IMMX vs SPAI Comparison
IMMX vs SPAI Comparison
Compare IMMX & SPAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- SPAI
- Stock Information
- Founded
- IMMX 2014
- SPAI 2021
- Country
- IMMX United States
- SPAI United States
- Employees
- IMMX N/A
- SPAI N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- SPAI Industrial Specialties
- Sector
- IMMX Health Care
- SPAI Health Care
- Exchange
- IMMX Nasdaq
- SPAI Nasdaq
- Market Cap
- IMMX 61.1M
- SPAI 61.4M
- IPO Year
- IMMX 2021
- SPAI 2024
- Fundamental
- Price
- IMMX $2.10
- SPAI $4.43
- Analyst Decision
- IMMX Strong Buy
- SPAI
- Analyst Count
- IMMX 1
- SPAI 0
- Target Price
- IMMX $7.00
- SPAI N/A
- AVG Volume (30 Days)
- IMMX 247.3K
- SPAI 577.8K
- Earning Date
- IMMX 11-12-2024
- SPAI 11-14-2024
- Dividend Yield
- IMMX N/A
- SPAI N/A
- EPS Growth
- IMMX N/A
- SPAI N/A
- EPS
- IMMX N/A
- SPAI N/A
- Revenue
- IMMX N/A
- SPAI $1,559,057.00
- Revenue This Year
- IMMX N/A
- SPAI N/A
- Revenue Next Year
- IMMX $200.00
- SPAI N/A
- P/E Ratio
- IMMX N/A
- SPAI N/A
- Revenue Growth
- IMMX N/A
- SPAI 35.50
- 52 Week Low
- IMMX $1.26
- SPAI $1.56
- 52 Week High
- IMMX $7.10
- SPAI $6.50
- Technical
- Relative Strength Index (RSI)
- IMMX 50.86
- SPAI N/A
- Support Level
- IMMX $2.04
- SPAI N/A
- Resistance Level
- IMMX $2.44
- SPAI N/A
- Average True Range (ATR)
- IMMX 0.31
- SPAI 0.00
- MACD
- IMMX -0.03
- SPAI 0.00
- Stochastic Oscillator
- IMMX 26.51
- SPAI 0.00
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About SPAI Safe Pro Group Inc. Common Stock
Safe Pro Group Inc operates to acquire security and protection products. Its emphasis is on the development of a cloud-based ecosystem for analyzing drone imagery and data utilizing proprietary artificial intelligence (AI), machine learning, deep learning, and applied computer vision software for hyper scalable processing, analysis, and reporting. The company operated in three reportable business segments which consisted of: the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. Key revenue is generated from Safe-Pro USA.